Question:

Are there any new pass-through drugs for the upcoming quarter?

Answer:

The Centers for Medicare & Medicaid Services (CMS) have granted outpatient prospective payment system (OPPS) pass-through status, effective July 1, 2018 the following drugs and biological:

C9030 Injection, copanlisib, 1 mg
C9031 Lutetium Lu 177, dotatate, therapeutic, 1 mCi
C9032 Injection, voretigene neparvovec-rzyl, 1 billion vector genome
Q9991 Injection, buprenorphine extendedrelease (Sublocade), less than or equal to 100 mg
Q9992 Injection, buprenorphine extendedrelease (Sublocade), greater than 100 mg
Q9995 Injection, emicizumab-kxwh, 0.5 mg

 

Facebook
Twitter
LinkedIn
Email
Print

CPT® copyright 2021 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.